Search results
Novavax stock doubles after Sanofi deal marks 'new chapter' for company
Yahoo Finance via AOL· 2 days agoWhile Novavax's vaccine did finally reach the market in mid-2022 targeting the booster market, it...
Novavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop...
CNBC· 2 days agoA health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization...
Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And Erases...
Benzinga via Yahoo Finance· 2 days agoThe terms of the agreement include: A co-exclusive license to co-commercialize Novavax’s current...
Novavax gets a lifeline with Sanofi vaccine pact
BioPharma Dive via Yahoo Finance· 2 days agoSanofi will ally with the under-pressure biotech, paying $500 million upfront for rights to co-commercialize Novavax’s COVID shot and develop combination...
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
WFRV 5 Green Bay· 2 days ago...combination product near-term milestones, plus ongoing tiered royalties on product salesUp to $200 million in milestones plus royalties for each new vaccine developed utilizing Novavax's Matrix-MTM adjuvantAnnounces addition of standalone influenza vaccine to Phase 3 COVID-19-Influenza...
Maryland-based Novavax soars on big vaccine deal - WTOP News
WTOP Washington· 2 days agoGaithersburg, Maryland-based Novavax has signed a $1.2 billion licensing agreement with French...
Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine...
CBS 47 Fresno· 2 days ago...Agreements and in India, Japan and South Korea where Novavax has existing partnership agreements); a sole license to Novavax's adjuvanted COVID-19 vaccine for use in combination with Sanofi's flu vaccines while Novavax retains the right to and is developing its own COVID-19-Influenza Combination ...
Novavax Inc (NVAX) Q1 2024 Earnings: Navigating Challenges with
Guru Focus· 2 days agoThe company, a prominent player in the biotechnology sector focusing on the development of vaccines, reported a net loss of $147.55 million with a loss per share of $1.05.
Novavax Inc (NVAX) Q1 2024 Earnings: Navigating Challenges with Strategic Partnerships and Cost ...
GuruFocus.com via Yahoo Finance· 2 days agoIn conclusion, Novavax Inc (NASDAQ:NVAX) is strategically maneuvering through financial and operational challenges by leveraging partnerships and refining its focus on core ...
The AstraZeneca vaccine – should you be worried?
The Telegraph via Yahoo News· 1 day agoEarlier this week, the European Commission announced that the Covid-19 vaccine, developed as part of a collaboration between the British pharma company...